当前位置：首页 > 产品中心

PEXG

PEXG

Addgene: pExG

Plasmid pExG from Dr Liqun Luo's lab contains the inserts GFP, tdTomato3Myc, betaglobin intron, and Hygro and is published in PLoS One 2012;7(3):e33332 Epub 2012 Overview of Addgene's educational resources, including eBooks, science Educational Resources

A randomized phase II trial of PEXG (cisplatin, epirubicin

2022年11月8日 Background: Fourdrug regimen significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard A novel chemotherapy regimen, PEXG, enhanced progressionfree survival compared to gemcitabine in 2005, and a phase II trial comparing PDXG vs PEXG showed both P163 Realworld outcomes of cisplatin Annals of Oncology

Realworld outcomes of cisplatin, capecitabine, and

This retrospective study in a realworld population demonstrates that chemotherapy with cisplatin, capecitabine, and gemcitabine with epirubicin (PEXG) or docetaxel (PDXG) had 2023年7月14日假性剥脱性青光眼 (PEXG)是一种严重危害视力的眼部疾病，较原发性开角型青光眼 (POAG)更具侵袭性，对视神经的损害更严重，预后更差，且对治疗有较高的耐假性剥脱性青光眼的生物标志物研究进展

Surgical Management of Pseudoexfoliative Glaucoma: A

2024年4月21日 Pseudoexfoliative glaucoma (PEXG) is the most common cause of secondary openangle glaucoma worldwide It is more aggressive and often more This retrospective study in a realworld population demonstrates that chemotherapy with cisplatin, capecitabine, and gemcitabine with epirubicin (PEXG) or docetaxel (PDXG) had similar effectiveness to more Real‐world outcomes of cisplatin, capecitabine,

Cisplatin, epirubicin, capecitabine, and gemcitabine (PEXG)

2014年5月20日 PEXG was administered on a fourweek cycle: cisplatin 30mg/m 2; epirubicin 30mg/m 2; gemcitabine 800 mg/m 2 on days 1 and 14, and capecitabine 2007年6月20日 A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma A randomized phase II trial of PEXG (cisplatin, epirubicin

AGENZIA ITALIANA DEL FARMACO COMMISSIONE

2020年1月9日 AGENZIA ITALIANA DEL FARMACO COMMISSIONE CONSULTIVA TECNICO SCIENTIFICA DETERMINAZIONE 19 dicembre 2019 Inserimento dello schema terapeutico PAXG (cisplatino, nabpaclitaxel, capecitabina, gemcitabina) 2023年11月16日 epirubicin(PEXG)41,folinicacid,5FUandoxaliplatin(FOLFOX)plus nabpaclitaxel 42 ,andcisplatin,gemcitabineandnabpaclitaxel 43 (Table 2)Anexcellentresponserateof397%hasalsobeenreportedNeoadjuvant therapy for pancreatic cancer Nature

A randomized phase II trial of two different 4drug Springer

2011年5月28日 We are further investigating the PEXG regimen in resectable pancreatic cancer randomizing patients to receive either 6 months of adjuvant gemcitabine or 6 months of adjuvant 4drug regimens or a perioperative treatment with the 4drug regimens for 3 months before and 3 months after surgery (NCT) We are also assessing the 2018年4月3日 Both preoperative and adjuvant PEXG resulted in more than 40% of patients being eventfree at 1 year, meeting the predefined criteria for success 3year and 5year overall survival with adjuvant therapy were in line with results from a previous phase 2 adjuvant trial that used a similar fourdrug regimen (PEFG, with fluorouracil instead of Safety and efficacy of preoperative or postoperative chemotherapy for

维吾尔族假性剥脱综合征患者角膜内皮形态学分析中华眼视

2021年6月25日选取2019年7月至2020年8月在中国人民解放军新疆军区总医院全军眼科中心就诊治疗的维吾尔族PEX患者76例（76眼），PEXG患者82例（82眼），POAG患者64例（64眼）以及ARC患者76例（76眼）分别作为PEX组、PEXG组、POAG组及ARC组。2023年6月17日编者按：剥脱综合征 (exfoliation syndrome,XFS)又称假性剥脱综合征，是一种过量物质在前房结构及整个身体中堆积的病症。 XFS是继发性开角型青光眼最常见的病因，称为假性剥脱性青光眼（XFG），其失明风险高于原发性开角型青光眼 (POAG)。环境因素和遗传改变的一文读懂，继发性青光眼常见病因——假性剥脱综合征

同源重组基因敲除单交换原理 PackGene Biotech

2月 18, 2024 同源重组基因敲除是一种常用的基因编辑技术，它通过引入外源DNA片段与目标基因的同源序列相互重组，从而实现对目标基因的敲除。本文将重点介绍同源重组基因敲除中的单交换原理，阐述其基本原理和应用。同源重组基因敲除的基本原理同源 Results We analyzed the sera of patients with PEXS and PEXG and controls for the presence of agonistic and inhibitory AAbs directed against the β 2ARNone of the control samples showed a β 2agAAb seropositivity (neither agonistic nor inhibitory) of 02 ± 05 U in the cardiomyocyte bioassayThe cutoff was set at mean ± 3 standard deviation of the Frontiers Inhibitory and Agonistic Autoantibodies Directed

数字校园统一身份认证用户登录

广东培正学院版权所有 © 2019Studio multicentrico randomizzato openlabel su 88 pazienti con adenocarcinoma duttale resecabile del pancreas di stadio III, con punteggio >60 sulla scala di Karnofsky Randomizzazione 1: 1: 1 a intervento + gemcitabina 1000 mg/m 2 nei giorni 1, 8, 15 ogni 4 settimane per 6 cicli (braccio A, n=26); intervento + 6 cicli di PEXG adiuvante Chemioterapia neoadiuvante per l’adenocarcinoma resecabile

A randomized phase II trial of PEXG (cisplatin, epirubicin

2007年6月20日 Request PDF A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma 4628 Background: Fourdrug L’8 Gennaio 2020 c'è stata la molto attesa pubblicazione sulla Gazzetta Ufficiale della delibera del protocollo PAXG dopo sei mesi dall’approvazione dell’AIFA Il protocollo PAXG risultato dello studio randomizzato di Fase Protocollo PAXG autorizzato e pubblicato su

Neoadjuvant therapy for pancreatic cancer Nature Reviews

2023年3月17日 A randomized phase II trial of two different 4drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)2019年12月30日 PAXG per l’adenocarcinoma del pancreas PAXG, la nuova combinazione di cisplatino, nabpaclitaxel, capecitabina e gemcitabina è stata approvata da AIFA per il trattamento dei pazienti con adenocarcinoma pancreatico Permette un miglioramento significativo della sopravvivenza (62% a 1 anno), con due soli accessi PAXG per l'adenocarcinoma del pancreas • NCF Notiziario

pEX1 载体图谱和序列纽普生物

下载GeneBank文件 (gb) LOCUS pEX1 4505 bp DNA circular SYN 01JAN1980 DEFINITION PrecisionShuttle(TM) bacterial vector for inducible expression of an untagged protein ACCESSION VERSION KEYWORDS pEX1 SOURCE synthetic DNA construct ORGANISM synthetic DNA construct2022年9月16日 Firstline palliative chemotherapy regimens in advanced pancreatic adenocarcinoma include triplet chemotherapy with 5fluorouracil, oxaliplatin, and irinotecan, and the doublet of nabpaclitaxel plus gemcitabine Use of triplet chemotherapy in realworld populations is limited by tolerability and nabpaclitaxel is not universally availableEurope PMC

振動式インライン粘度計 FEM1000Vシリーズ：粘度計：製品

2023年1月30日 FVM80APEXG ExdⅡCT6 TC18354 FEM1000EXSC ExdⅡBT6 TC18851 耐酸性、耐アルカリ性、耐油性、付着防止等液条件に応じてプローブの材質等対応可能です。コントローラにはPLL回路（Phased Lock Loop）を採用し、発信周波数は常に振動子の共振周波 2021年3月1日 Introduction: Pseudoexfoliative glaucoma (PEXG) is the most common cause of secondary openangle glaucoma worldwide It is more aggressive and often more resistant to conventional treatments than primary openangle glaucoma, yet there is currently no clear consensus on best management practicesSurgical Management of Pseudoexfoliative Glaucoma: A

胰腺癌综合治疗新进展（中）辅助

2019年8月16日新辅助治疗患者，若2～3个月肿瘤进展迅速或治疗反应差，被认为即使直接手术亦很难获益，从而起到筛选作用，避免这部分患者不必要的手术创伤。因此，新辅助治疗既是筛选又是治疗，是胰腺外科医师在临床实践过程中的一把锐利武器。 23 新辅助治疗 2024年6月6日 Sistema de Indicação Sistema de Captura World Trade World Transfer Sistema de Pokémon T1H Pokémon Obtidos via NPC Cyber DungeonPokeXGames

Neoadjuvant Treatment for Resectable and Borderline

2022年2月14日 The median overall survival was 204 months after surgery and adjuvant gemcitabine, versus 264 months in the adjuvant PEXG group, and 382 months in the neoadjuvant group This study did not continue to phase III trial, because new, more effective chemotherapy regimens were developed The multicenter randomized phase 2023年10月7日 Purpose To compare clinical outcomes between gonioscopyassisted transluminal trabeculotomy (GATT) and trabeculectomy (TRAB) in patients with advancedstage pseudoexfoliation glaucoma (PEXG) Methods This comparative study comprised 62 patients who underwent GATT (N = 31) or TRAB (N = 31) for advancedstage PEXG Comparison of clinical outcomes between gonioscopy

Linee Guida 2019 Pancreas AIOM

2023年1月22日 PEXG (3 cicli) preoperatorio chirurgica PEXG (3 cicli) postoperatorio CARCINOMA DEL PANCREAS ESOCRINO LINEE GUIDA 2019 10 Figura 3: Malattia Borderline Resectable Malattia “borderline resectable” 2023年1月22日 PEXG (3 cicli) preoperatorio dopo accertamento bioptico: chirurgica: PEXG (3 cicli) postoperatorio: CARCINOMA DEL PANCREAS ESOCRINO LINEE GUIDA 2020 : 10: Figura 3: Malattia Borderline Resectable: Malattia “borderline resectable” Linee Guida 2020 Pancreas AIOM

Evaluation of aqueous humor and serum clusterin levels in patients with

2021年1月9日 Background To compare the aqueous humor (AH) and the serum clusterin levels of patients with pseudoexfoliation syndrome (PEX), pseudoexfoliation glaucoma (PEXG), and primary openangle glaucoma (POAG) with each other and with an age and sexmatched control group Methods This prospective, crosssectionalstudy evaluated 92 2020年3月3日 By analyzing the bisulfite sequencing of 12 control, 10 PEXS, and 3 PEXG samples for each region, it was found that in PEXS, region III displayed hypermethylation (311%) in comparison with the Epigenetic silencing of heat shock protein 70 through DNA

Tumore del pancreas: disponibile nuova chemioterapia PAXG

2020年1月24日 Che cos’è lo schema PAXG La chemioterapia costituisce la principale arma per combattere il tumore al pancreas La nuova formula PAXG prevede la combinazione di quattro farmaci (cisplatino, nabpaclitaxel, capecitabina, gemcitabina) ed è il risultato di studi clinici indipendenti condotti e coordinati dal dottor Michele Reni, del Methods: Chemonaive patients with stage III or metastatic PA received P (30 mg/m(2) day 1 and 15), G (800 mg/m(2) day 1 and 15), and capecitabine (1,250 mg/m(2)/day days 128, without a break) and were randomized to receive either D at 2530 mg/m(2) day 1 and 15 (arm A: PDXG regimen) or E at 30 mg/m(2) day 1 and 15 (arm B: PEXG regimen A randomized phase II trial of two different 4drug PubMed

Cisplatin, epirubicin, capecitabine, and gemcitabine (PEXG)

2014年5月20日 A dosedense PEXG schedule (capecitabine substituted for 5FU) showed similar efficacy (Reni, 2012) with a more acceptable toxicity profile FOLFIRINOX is an active regimen, but has not been uniformly adopted at published doses due to concerns about toxicity Many institutions therefore prefer the combination of gemcitabine and nab PDXG/PEXG are viable alternatives to nabpaclitaxel plus gemcitabine in countries that have restricted drug funding CONFLICT OF INTEREST All authors have completed the ICMJE uniform disclosure form The authors have no conflicts Real‐world outcomes of cisplatin, capecitabine, and

新疆地区维吾尔族假性剥脱综合征患者眼前节参数分析比较

2021年11月20日目的探索新疆地区维吾尔族假性剥脱综合征（PEX）、剥脱性青光眼（PEXG）、原发性开角型青光眼（POAG）及年龄相关性白内障患者眼前节参数的差异。方法采用回顾性研究方法，选取2019年4月至2020年7月在中国人民解放军新疆军区总医院全军眼科中心就诊治疗 Disclaimer: The NCBI taxonomy database is not an authoritative source for nomenclature or classification please consult the relevant scientific literature for the most reliable information Reference: How to cite this resource Schoch CL, et al NCBI Taxonomy: a comprehensive update on curation, resources and toolsDatabase (Oxford) 2020: baaa062Taxonomy browser (Cloning vector pEXG2) National Center

Association of IL10 gene promoter polymorphisms with

2020年2月12日 Pseudoexfoliation (PEX) syndrome, as an agerelated disorder of the extracellular matrix is characterized by pathologic accumulation of abnormal fibrillar material in various intra and extraocular tissues []PEX syndrome is the most common cause of secondary glaucoma, named pseudoexfoliative glaucoma (PEXG) which is considered 2014年5月20日 A dosedense PEXG schedule (capecitabine substituted for 5FU) showed similar efficacy (Reni, 2012) with a more acceptable toxicity profile FOLFIRINOX is an active regimen, but has not been uniformly adopted at published doses due to concerns about toxicity Many institutions therefore prefer the combination of gemcitabine and nab Cisplatin, epirubicin, capecitabine, and gemcitabine (PEXG)

A randomized phase II trial of PEXG (cisplatin, epirubicin

2007年6月20日 The current study was an attempt to further improve progressionfree survival (PFS) by replacing epirubicin with docetaxel in patients with advanced pancreatic adenocarcinoma 4628 Background: Fourdrug regimen significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard 2021年8月16日 Introduction Pancreatic ductal adenocarcinoma (PDAC) is a candidate for the second leading cause of cancerrelated death in 2030, with a fiveyear survival rate of 57% ( 1 ) Surgical treatment with the goal of radical resection tumorfree excision margins (so called “R0 resection”) is the only potentially curative approach for PDACAdjuvant Treatment in Pancreatic Cancer: Shaping the Future

Comparison of longterm results of trabeculectomy and

2022年1月27日 Primary openangle glaucoma is the most common form of glaucoma Pseudoexfoliation glaucoma (PEXG) is the most known cause of openangle glaucoma caused by pseudoexfoliation syndrome (PEXS) which is an agerelated ocular disease marked by accumulation and deposition of pseudoexfoliative material over different Looking for online definition of PEXG or what PEXG stands for? PEXG is listed in the World's most authoritative dictionary of abbreviations and acronyms The Free DictionaryPEXG What does PEXG stand for? The Free Dictionary

Pseudoexfoliative glaucoma: epidemiology,

2023年1月1日 102 Introduction Pseudoexfoliative glaucoma (PEXG) is the most frequent type of secondary openangle glaucoma and the most common identifiable cause of openangle glaucoma worldwide, accounting for about 25% of openangle glaucomas overall (Ritch, 1994)In some countries like Norway, Ireland, Greece, Saudi Arabia, and Oman, 2019年7月29日 However, there is no difference (p = 036) in the level of FBLN5 between control and PEXG subjects (Fig 1b, c) Fig 1 mRNA and protein expression of FBLN5 in the lens capsule of cases and controlsDe novo variants in an extracellular matrix protein coding gene

AGENZIA ITALIANA DEL FARMACO COMMISSIONE

A randomized phase II trial of two different 4drug Springer

一文读懂，继发性青光眼常见病因——假性剥脱综合征

2023年6月17日编者按：剥脱综合征 (exfoliation syndrome,XFS)又称假性剥脱综合征，是一种过量物质在前房结构及整个身体中堆积的病症。 XFS是继发性开角型青光眼最常见的病因，称为假性剥脱性青光眼（XFG），其失明风险高于原发性开角型青光眼 (POAG)。环境因素和遗传改变的 2月 18, 2024 同源重组基因敲除是一种常用的基因编辑技术，它通过引入外源DNA片段与目标基因的同源序列相互重组，从而实现对目标基因的敲除。本文将重点介绍同源重组基因敲除中的单交换原理，阐述其基本原理和应用。同源重组基因敲除的基本原理同源同源重组基因敲除单交换原理 PackGene Biotech

Frontiers Inhibitory and Agonistic Autoantibodies Directed

Results We analyzed the sera of patients with PEXS and PEXG and controls for the presence of agonistic and inhibitory AAbs directed against the β 2ARNone of the control samples showed a β 2agAAb seropositivity (neither agonistic nor inhibitory) of 02 ± 05 U in the cardiomyocyte bioassayThe cutoff was set at mean ± 3 standard deviation of the 广东培正学院版权所有 © 2019数字校园统一身份认证用户登录

Chemioterapia neoadiuvante per l’adenocarcinoma resecabile

Studio multicentrico randomizzato openlabel su 88 pazienti con adenocarcinoma duttale resecabile del pancreas di stadio III, con punteggio >60 sulla scala di Karnofsky Randomizzazione 1: 1: 1 a intervento + gemcitabina 1000 mg/m 2 nei giorni 1, 8, 15 ogni 4 settimane per 6 cicli (braccio A, n=26); intervento + 6 cicli di PEXG adiuvante

神魔样的东西是梯形的神魔样的东西是梯形的神魔样的东西是梯形的

粉体企业生产线恒安